Assessing Bone Formation on Hydrophilic and Hydrophobic Implant Surfaces in a Murine Model Treated with Bisphosphonates

Overview

Journal Clin Oral Investig

Specialty Dentistry

Date 2024 Jan 13

PMID 38217802

Authors

Julio Cesar Sanchez-Puetate

Bruno Luis Graciliano Silva

Felipe Eduardo Pinotti

Camila Chierici Marcantonio

Guilherme Jose Pimentel Lopes de Oliveira

Elcio Marcantonio Junior

Rosemary Adriana Chierici Marcantonio

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the osseointegration of implants with hydrophobic (HFB) and hydrophilic (HFL) surfaces in a murine model of high-dose bisphosphonates (BPs).

Materials And Methods: Sixty-four rats were randomly allocated into four groups: control group with HFB implants (CG-HFB), control group with HFL implants (CG-HFL), BP group with HFB implants (BP-HFB), and BP group with HFL implants (BP-HFL). Animals were euthanized after 15 and 45 days (n=8). The dependent variables assessed were the removal torque (biomechanical analysis), the bone volume around the implants (%BV/TV) (microtomographic analysis), the bone-implant contact (%BIC), the bone between the threads (%BBT) (histomorphometric analysis), and the expression of bone metabolism markers (immunohistochemistry analysis).

Results: The CG-HFL and BP-HFL groups presented higher removal torque than the CG-HFB and BP-HFB implants. The %BIC of the CG-HFL surfaces was slightly higher than that of the CG-HFB implants. The BP-HFB and BP-HFL groups presented a higher %BIC than that of the CG-HFB and CG-HFL groups (p<0.001). BP therapy also increased the %BBT at both implant surfaces. Higher levels of ALP were observed in the matrix region of bone tissue on the HFL surfaces than on the HFB surfaces.

Conclusion: Both surfaces enable osseointegration in rats under BP therapy.

Clinical Relevance: The study demonstrates that hydrophobic (HFB) and hydrophilic (HFL) implant surfaces can promote osseointegration in rats undergoing bisphosphonate therapy. The HFL surfaces exhibited improved biomechanical performance, higher bone-implant contact, and increased bone volume, suggesting their potential clinical relevance for implant success in individuals on bisphosphonate treatment.

Citing Articles

Analysis of peri-implant bone tissue between hydrophilic and rough implant surfaces in spontaneously hypertensive rats treated with losartan.

Santos J, Mulinari-Santos G, de Souza Batista F, Gomes-Ferreira P, Palin L, Antoniali C J Appl Oral Sci. 2024; 32:e20230374.

PMID: 38922240 PMC: 11182640. DOI: 10.1590/1678-7757-2023-0374.

Different Methods to Modify the Hydrophilicity of Titanium Implants with Biomimetic Surface Topography to Induce Variable Responses in Bone Marrow Stromal Cells.

Jacobs T, Dillon J, Cohen D, Boyan B, Schwartz Z Biomimetics (Basel). 2024; 9(4).

PMID: 38667238 PMC: 11048143. DOI: 10.3390/biomimetics9040227.

References

Lane N . Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 2006; 194(2 Suppl):S3-11. DOI: 10.1016/j.ajog.2005.08.047. View

Tolia M, Zygogianni A, Kouvaris J, Meristoudis C, Margari N, Karakitsos P . The key role of bisphosphonates in the supportive care of cancer patients. Anticancer Res. 2014; 34(1):23-37. View

Neto N, Spolidorio L, Andrade C, Bastos A, Guimaraes M, Marcantonio Jr E . Experimental development of bisphosphonate-related osteonecrosis of the jaws in rodents. Int J Exp Pathol. 2013; 94(1):65-73. PMC: 3575875. DOI: 10.1111/iep.12007. View

Tella S, Gallagher J . Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 2013; 142:155-70. PMC: 4187361. DOI: 10.1016/j.jsbmb.2013.09.008. View

Hughes D, Wright K, Uy H, Sasaki A, Yoneda T, Roodman G . Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995; 10(10):1478-87. DOI: 10.1002/jbmr.5650101008. View

Reszka A, Masarachia P, Rodan G . Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem. 1999; 274(49):34967-73. DOI: 10.1074/jbc.274.49.34967. View

Boonekamp P, Thesing C, BIJVOET O . Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner. 1986; 1(1):27-39. View

Colucci S, Minielli V, Zambonin G, Cirulli N, Mori G, Serra M . Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces. Calcif Tissue Int. 1998; 63(3):230-5. DOI: 10.1007/s002239900519. View

Flanagan A, Chambers T . Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int. 1991; 49(6):407-15. DOI: 10.1007/BF02555852. View

10.

Piper K, Boyde A, Jones S . The effect of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (ADP) on the resorptive function of osteoclasts of known nuclear number. Calcif Tissue Int. 1994; 54(1):56-61. DOI: 10.1007/BF00316291. View

11.

Maruotti N, Corrado A, Neve A, Cantatore F . Bisphosphonates: effects on osteoblast. Eur J Clin Pharmacol. 2012; 68(7):1013-8. DOI: 10.1007/s00228-012-1216-7. View

12.

Ohe J, Kwon Y, Lee H . Bisphosphonates modulate the expression of OPG and M-CSF in hMSC-derived osteoblasts. Clin Oral Investig. 2011; 16(4):1153-9. DOI: 10.1007/s00784-011-0614-z. View

13.

Viereck V, Emons G, Lauck V, Frosch K, Blaschke S, Grundker C . Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun. 2002; 291(3):680-6. DOI: 10.1006/bbrc.2002.6510. View

14.

Roelofs A, Thompson K, Gordon S, Rogers M . Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res. 2006; 12(20 Pt 2):6222s-6230s. DOI: 10.1158/1078-0432.CCR-06-0843. View

15.

Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M . Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002; 62(22):6538-44. View

16.

Ledoux D, Hamma-Kourbali Y, Di Benedetto M, Foucault-Bertaud A, Oudar O, Sainte-Catherine O . A new dimethyl ester bisphosphonate inhibits angiogenesis and growth of human epidermoid carcinoma xenograft in nude mice. Anticancer Drugs. 2006; 17(4):479-85. DOI: 10.1097/01.cad.0000198909.52701.0f. View

17.

Vincenzi B, Santini D, Rocci L, Tonini G . Bisphosphonates: new antiangiogenic molecules in cancer treatment?. Ann Oncol. 2003; 14(5):806-7. DOI: 10.1093/annonc/mdg194. View

18.

Cackowski F, Anderson J, Patrene K, Choksi R, Shapiro S, Windle J . Osteoclasts are important for bone angiogenesis. Blood. 2009; 115(1):140-9. PMC: 3988688. DOI: 10.1182/blood-2009-08-237628. View

19.

Kapitola J, Zak J . Effect of pamidronate on bone blood flow in oophorectomized rats. Physiol Res. 1998; 47(4):237-40. View

20.

Rogers J, Stewart P, Stapleton J, Hribar D, Adams P, Gale A . An interdisciplinary approach to the management of complex medical and dental conditions. Aust Dent J. 2001; 45(4):270-6. DOI: 10.1111/j.1834-7819.2000.tb00262.x. View